The company’s Wood Lane location has expanded apheresis, whole blood, and plasma collection capabilities, as well as an on-site cell isolation laboratory
Research and diagnostics service provider BioIVT will be hosting an open house from 7-9 pm on February 23. Hosted at the Scale Space venue at 58 Wood Lane, London W12 7RZ, staff will accompany attendees on guided tours of the company’s laboratories and blood donor centre so researchers can see how its biospecimens are collected and processed.
The event has been organised to celebrate a partnership with One Nucleus, a not-for-profit life science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster in the UK.
“This open house will provide an excellent opportunity for our members to view BioIVT’s new facilities and learn how the company has become a critical supplier of leukopaks, immune cells, and other biospecimens for medical researchers in the UK and Europe. They will discover different ways in which BioIVT can support their research and development of advanced therapeutics going forward,” said Tony Jones, CEO of One Nucleus.
BioIVT’s Wood Lane location has expanded apheresis, whole blood, and plasma collection capabilities, as well as an on-site cell isolation laboratory. The company says it has already received blood donations from more than 500 people at the center, and expects to work with up to 40 donors a day.
“Taken together, these capabilities enable us to provide fresh, well-characterised leukopaks, immune cells, and other biospecimens to local researchers in the UK and EU, thus reducing cryopreservation and shipping costs, whilst maximising biological relevancy,” said Trevor Smith, MS, MBA, Product Manager, Immune Cell Portfolio at BioIVT.
The company offers UK collected leukopaks through its Clinical Trials Laboratory Services business), however it can also source mobilised and disease state leukopaks and immune cells from US donor sites and a global clinical collections network when required.
The company’s product portfolio is designed to support cell and gene therapy research regardless of the cell type, indication, or stage of development. It also offers characterisation services including high-definition HLA typing, Fc receptor genotyping, and CMV IgG serology.